普米克令舒与多索茶碱在慢阻肺患者急性加重期的应用价值及对炎症指标的改善效果评价  

Application Value of Pulmicort and Doxofylline in Acute Exacerbation of COPD Patients,and the Effect Evaluation of the Improvement of Inflammation Index

作　　者：韦红梅[1] Wei Hongmei(Hebei Province Anguo City Hospital, Anguo 071200, China)

机构地区：[1]河北省安国市医院,河北安国071200

出　　处：《黑龙江科学》2022年第2期80-81,共2页Heilongjiang Science

摘　　要：研究对慢阻肺急性加重期患者实施普米克令舒与多索茶碱治疗干预后患者的临床疗效及炎性指标改善情况。选取98例慢阻肺急性加重期患者,将其分为研究组和参照组,每组各49例。研究组给予普米克令舒与多索茶碱治疗干预,参照组单纯给予多索茶碱治疗干预,对比两组患者的临床疗效及炎性指标改善效果。干预结束后,研究组的临床疗效及炎性指标显著优于参照组(P<0.05),差异均具有统计学意义。对慢阻肺急性加重期患者实施普米克令舒与多索茶碱治疗干预,可有效提高患者的临床疗效,降低其炎性指标。The study analyzes the clinical effect of pulmicort and doxofylline in acute exacerbation of COPD patients,and the index improvement situation.98 patients with acute exacerbation of COPD patients are selected,and they are divided into research group and control group,with 49 patients in each group.Research group receive pulmicort and doxofylline treatment,and control group receive doxofylline treatment intervention.Clinical effect and the improvement effect of inflammatory index of two groups are compared.After intervention,the clinical effect and inflammatory index of research group are significantly better than control group,with statistically significant difference(P<0.05).Pulmicort and doxofylline in acute exacerbation of COPD patients can effectively improve the clinical effect of patients,and reduce the inflammatory index.

关 键 词：普米克令舒 多索茶碱 慢阻肺急性加重期患者 应用效果 评价指标 

分 类 号：R56[医药卫生—呼吸系统]